[1] |
WANG Zifei, DING Yahui, LI Yan, LUAN Xin, TANG Min.
Application of 3D bioprinting in cancer research and tissue engineering
[J]. China Oncology, 2024, 34(9): 814-826.
|
[2] |
XU Rui, WANG Zehao, WU Jiong.
Advances in the role of tumor-associated neutrophils in the development of breast cancer
[J]. China Oncology, 2024, 34(9): 881-889.
|
[3] |
GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo.
The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer
[J]. China Oncology, 2024, 34(8): 745-752.
|
[4] |
CAO Fei, YU Wenhao, TANG Xiaonan, MA Zidong, CHANG Tingmin, GONG Yabin, LIAO Mingjuan, KANG Xiaohong.
Mechanism of LINC01410 promoting proliferation and migration in esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(8): 753-762.
|
[5] |
XIAO Yi, WU Ming, YAO Gang.
Research progress and future perspectives of tumor organoid
[J]. China Oncology, 2024, 34(8): 763-776.
|
[6] |
WANG Manli, CHEN Hui, DUAN Zhi, XU Qimei, LI Zhen.
A study on communication mechanism of lung cancer cells in tumor microenvironment mediated by pleckstrin-2/miR-196a signal axis
[J]. China Oncology, 2024, 34(7): 628-638.
|
[7] |
PAN Jian, YE Dingwei, ZHU Yao, WANG Beihe.
Correlation analysis of PSMA PET/CT-derived parameters and circulating tumor DNA features in patients with hormone-sensitive prostate cancer
[J]. China Oncology, 2024, 34(7): 680-685.
|
[8] |
LIANG Yingyun, CHEN Jianhua.
Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors
[J]. China Oncology, 2024, 34(7): 686-694.
|
[9] |
HU Feixiang, TONG Tong, PENG Weijun.
The latest progress and prospects of 2D MXenes materials in the application of tumor diagnosis and treatment
[J]. China Oncology, 2024, 34(6): 598-606.
|
[10] |
WANG Xiaocong, LI Ming.
The value of single-cell sequencing in oral squamous cell carcinoma research
[J]. China Oncology, 2024, 34(5): 501-508.
|
[11] |
XIN Meiyi, LIN Yuhong, ZHAO Kai.
Progress in the development of mRNA vaccine and its delivery systems for anti-tumor immunotherapy
[J]. China Oncology, 2024, 34(5): 509-516.
|
[12] |
XU Yonghu, XU Dazhi.
Progress and prospects of gastric cancer treatment in the 21st century
[J]. China Oncology, 2024, 34(3): 239-249.
|
[13] |
LI Jing, ZHENG Lei, GAO Yu.
Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer
[J]. China Oncology, 2024, 34(3): 286-292.
|
[14] |
CHEN Yifan, LI Ting, WANG Biyun.
Research progress of CCR8 in tumor immunotherapy
[J]. China Oncology, 2024, 34(3): 299-305.
|
[15] |
LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng.
Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
[J]. China Oncology, 2024, 34(2): 191-200.
|